1 Apr 2021 07:05
1 April 2021
ย
RTW Venture Fund Limited
(the "Company")
ย
TOTAL VOTING RIGHTS
ย
In accordance with DTR 5.6.1R as at 31 March 2021 the Company had 204,047,167 Ordinary Shares in issue, each with equal voting rights and no shares held in Treasury.
ย
The total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
ย
For further information, please contact:
ย
RTW Investments, LP +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
ย
Elysium Fund Management Limited +44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
ย
Morgan Stanley Fund Services USA LLC +1 (914) 225-8885
ย
J.P. Morgan Cazenove +44 (0) 20 7742 4000
William Simmonds
James Bouverat (Sales)
ย
Barclays +44 (0) 20 7623 2323
Tom Swerling
Andrew Tusa
ย
ย
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
ย
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment ๏ฌrm with deep scienti๏ฌc expertise and a strong track record of supporting companies developing life-changing therapies.
ย
Visit the RTW website at www.rtwfunds.com for more information.
ย
Follow the stocks